ArticleBioelectrochemistry (Amsterdam, Netherlands)2022
Design and simulation of a millifluidic device for differential detection of SARS-CoV-2 and H1N1 based on triboelectricity.
Article in Bioelectrochemistry (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence-powered electrochemical sensor: Recent advances, challenges, and prospects.Heliyon · 2024Review
- Internet-of-medical-things integrated point-of-care biosensing devices for infectious diseases: Toward better preparedness for futuristic pandemics.Bioengineering & translational medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differential diagnosis of pathogenic diseases, presently coronavirus disease 2019 (COVID-19) and influenza, is crucial with due attention to their superspreading events, presumably long incubation period, particular complications, and treatments. In this paper, a label-free, self-powered, and ultrafast immunosensor device working based on triboelectric effect is proposed. Equilibrium constants of specific antibody-antigen reactions are accompanied by IEP-relevant electric charges of antigens to recognize SARS-CoV-2 and H1N1. Simulation attributes including fluid flow and geometrical parameters are optimized so that the maximum capture efficiency of 85.63% is achieved. Accordingly, antibody-antigen complexes form electric double layers (EDLs) across the channel interfaces. The resultant built-in electric field affects the following external electric field derived from triboelectricity, leading to the variation of open-circuit voltage as a sensing metric. The device is flexible to operate in conductor-to-dielectric single-electrode and contact-separation modes simultaneously. While the detection limit is reduced utilizing the single-electrode mode compared to the latter one, surface treatment of the triboelectric pair contributes to the sensitivity enhancement. A threshold value equal to -4.113 V is featured to discriminate these two viruses in a vast detectable region; however, further surface engineering can allow the on-site detection of any electrically-charged pathogen applying the emerging triboelectric immunosensor enjoying a lower detection limit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.